Redefining the Position of Hormonal Therapy in Endometrial Cancer in the Era of Molecular Classification

Pijnenborg, Johanna M.A.; van Weelden, Willem Jan; Reijnen, Casper; Xanthoulea, Sofia; Romano, Andrea

doi:10.1200/jco.23.00470

Cited by 5 publications

(3 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hormonal response and endometrial regeneration also disappear in cases of Asherman's syndrome and a thin endometrium due to disruptions of endometrial cell composition [ 22 ]. Additionally, during the development of endometrial cancer, an imbalance in hormone sensitivity results in excessive endometrial proliferation, which subsequently leads to uncontrolled endometrial hyperplasia [ 23 ]. Therefore, studies focusing on the injured endometrium are needed to provide insights into the mechanisms involved in the development and survival of diseased tissues.…”

Section: Structure and Composition Of The Endometriummentioning

confidence: 99%

Bioengineering approaches for the endometrial research and application

Dai,

Liang,

Guo

et al. 2024

Materials Today Bio

View full text Add to dashboard Cite

Section: Structure and Composition Of The Endometriummentioning

confidence: 99%

Bioengineering approaches for the endometrial research and application

Dai,

Liang,

Guo

et al. 2024

Materials Today Bio

View full text Add to dashboard Cite

“…Besides this, receptor status is still not routinely assessed prior to treatment, and there is no consensus on the optimal cut-off value for hormone receptor positivity (ER/PR) in EC [ 20 , 21 , 29 ]. In addition, the molecular classification has further challenged the position of hormonal therapy [ 30 , 31 , 32 , 33 ].…”

Section: Introductionmentioning

confidence: 99%

“…As metastases often exhibit heterogeneity compared to the primary tumour, the reassessment of hormone receptor status within metastases is recommended [ 23 , 34 , 35 , 36 ]. The analysis of ER/PR-IHC expression and ERPAS at different tumour locations can improve the understanding of cancer spread and help refine patient selection for hormonal therapy [ 33 ]. Therefore, we evaluated ER/PR-IHC expression and ERPAS between different tumour locations in advanced and recurrent EC collected in the PROMOTE-study [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma

Luijten,

van Weelden,

Lalisang

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

Background: Response to hormonal therapy in advanced and recurrent endometrial cancer (EC) can be predicted by oestrogen and progesterone receptor immunohistochemical (ER/PR-IHC) expression, with response rates of 60% in PR-IHC > 50% cases. ER/PR-IHC can vary by tumour location and is frequently lost with tumour progression. Therefore, we explored the relationship between ER/PR-IHC expression and tumour location in EC. Methods: Pre-treatment tumour biopsies from 6 different sites of 80 cases treated with hormonal therapy were analysed for ER/PR-IHC expression and classified into categories 0–10%, 10–50%, and >50%. The ER pathway activity score (ERPAS) was determined based on mRNA levels of ER-related target genes, reflecting the actual activity of the ER receptor. Results: There was a trend towards lower PR-IHC (33% had PR > 50%) and ERPAS (27% had ERPAS > 15) in lymphogenic metastases compared to other locations (p = 0.074). Hematogenous and intra-abdominal metastases appeared to have high ER/PR-IHC and ERPAS (85% and 89% ER-IHC > 50%; 64% and 78% PR-IHC > 50%; 60% and 71% ERPAS > 15, not significant). Tumour grade and previous radiotherapy did not affect ER/PR-IHC or ERPAS. Conclusions: A trend towards lower PR-IHC and ERPAS was observed in lymphogenic sites. Verification in larger cohorts is needed to confirm these findings, which may have implications for the use of hormonal therapy in the future.

show abstract